-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
Trial Shows Oral Covid-19 Vaccine Produces Antibodies
A clinical trial shows a Covid-19 vaccine taken as a tablet produces protective antibodies in nasal membranes that in some cases last for up to a year.
-
Synthetic Bio Microbiome Biotech Gains $15M in Seed Funds
A developer of therapies produced with synthetic biology for diseases linked to microbes in the gut is raising $15 million in seed financing.
-
Impress vs competitors, why is it the best option?
Impress offers patients treatment for complex cases such as overcrowding, abnormal spacing, and bite malalignment, as well as diagnostics like X-Rays before treatment.
-
Surgical Robotics Company Raises $55M in Early Funds
A developer of robotic systems for cataract and other eye surgeries is raising $55 million in its first venture financing round.
-
Four Issues Holding Back Small Businesses
Do you feel as though your company is being held back? If so, then you are not alone.
-
Infographic – US Biotech Investments Stay Strong
The first half half of 2022 shows venture investments in U.S. biotechnology start-ups cooled from the blistering pace of last year, but biotech remains a robust sector.
-
NIH Funding Engineered Phage Screening Device
National Institutes of Health is funding initial development of a microfluidic device that tests engineered viruses for their ability to kill disease-causing bacteria.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.
-
Biotechs Explore Gut-Brain Axis for Mental Health
Two biotechnology companies are advancing basic research findings connecting gut microbes with the brain to develop new therapies for neurological disorders.